NCT06925048View on ClinicalTrials.gov

SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-Small Cell Lung CancerJAK InhibitorImmunology
Interventions
DRUG

PD-1 inhbitor+SHR0302

PD-1 inhbitor+SHR0302 in the maintenance treatment

DRUG

PD-L1 inhibitor+SHR0302

PD-L1 inhibitor+SHR0302 in second line

All Listed Sponsors
lead

Chunxia Su

OTHER

NCT06925048 - SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC | Biotech Hunter | Biotech Hunter